Impact of heptavalent pneumococcal conjugate vaccine on invasive disease, antimicrobial resistance and colonization in Alaska Natives: progress towards elimination of a health disparity.

[1]  A. Schuchat,et al.  Impact of a conjugate vaccine on community-wide carriage of nonsusceptible Streptococcus pneumoniae in Alaska. , 2004, The Journal of infectious diseases.

[2]  H. Verbrugh,et al.  Colonisation by Streptococcus pneumoniae and Staphylococcus aureus in healthy children , 2004, The Lancet.

[3]  Jody M. Chattin,et al.  Hepatitis A incidence and hepatitis a vaccination among American Indians and Alaska Natives, 1990-2001. , 2004, American journal of public health.

[4]  B. Zhu,et al.  Impact of PCV7 on invasive pneumococcal disease among children younger than 5 years: a population-based study. , 2004, American journal of public health.

[5]  S. Schrag,et al.  Impact of childhood vaccination on racial disparities in invasive Streptococcus pneumoniae infections. , 2004, JAMA.

[6]  R. Donlan,et al.  Community-onset methicillin-resistant Staphylococcus aureus associated with antibiotic use and the cytotoxin Panton-Valentine leukocidin during a furunculosis outbreak in rural Alaska. , 2004, The Journal of infectious diseases.

[7]  R. de Groot,et al.  Streptococcus pneumoniae colonisation: the key to pneumococcal disease. , 2004, The Lancet. Infectious diseases.

[8]  B. McMahon,et al.  The Relationship among Previous Antimicrobial Use, Antimicrobial Resistance, and Treatment Outcomes for Helicobacter pylori Infections , 2003, Annals of Internal Medicine.

[9]  K. O'Brien,et al.  Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial , 2003, The Lancet.

[10]  R. Dagan,et al.  Effect of a nonavalent conjugate vaccine on carriage of antibiotic-resistant Streptococcus pneumoniae in day-care centers , 2003, The Pediatric infectious disease journal.

[11]  A. Schuchat,et al.  Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. , 2003, The New England journal of medicine.

[12]  J. Janosky,et al.  Incidence of invasive pneumococcal disease in children 3 to 36 months of age at a tertiary care pediatric center 2 years after licensure of the pneumococcal conjugate vaccine. , 2003, Pediatrics.

[13]  B. Schwartz,et al.  Changes in antibiotic-prescribing practices and carriage of penicillin-resistant Streptococcus pneumoniae: A controlled intervention trial in rural Alaska. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  B. Schwartz,et al.  Effect of high-dose amoxicillin on the prevalence of penicillin-resistant Streptococcus pneumoniae in rural Alaska. , 2002, JAMA.

[15]  S. Black,et al.  Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine , 2001, The Pediatric infectious disease journal.

[16]  P. Chyou,et al.  A community intervention trial to promote judicious antibiotic use and reduce penicillin-resistant Streptococcus pneumoniae carriage in children. , 2001, Pediatrics.

[17]  K. Klugman.  Efficacy of pneumococcal conjugate vaccines and their effect on carriage and antimicrobial resistance. , 2001, The Lancet. Infectious diseases.

[18]  R. Singleton,et al.  Experience with the prevention of invasive Haemophilus influenzae type b disease by vaccination in Alaska: the impact of persistent oropharyngeal carriage. , 2000, The Journal of pediatrics.

[19]  J. Butler,et al.  Serotype distribution and antimicrobial resistance patterns of invasive isolates of Streptococcus pneumoniae: Alaska, 1991-1998. , 2000, The Journal of infectious diseases.

[20]  D. Greenberg,et al.  Immunogenicity of a heptavalent pneumococcal conjugate vaccine in Apache and Navajo Indian, Alaska native, and non-native American children aged <2 years. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  R. Singleton,et al.  Invasive Haemophilus influenzae disease in Alaskan residents aged 10 years and older before and after infant vaccination programs. , 2000, JAMA.

[22]  E. Lewis,et al.  Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children , 2000, The Pediatric infectious disease journal.

[23]  H. Margolis,et al.  Elimination of new chronic hepatitis B virus infections: results of the Alaska immunization program. , 2000, The Journal of infectious diseases.

[24]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .

[25]  S. Dowell,et al.  Acute otitis media: management and surveillance in an era of pneumococcal resistance--a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group. , 1999, The Pediatric infectious disease journal.

[26]  Y. Tung,et al.  Relationship between nasopharyngeal colonization and the development of otitis media in children. Tonawanda/Williamsville Pediatrics. , 1997, The Journal of infectious diseases.

[27]  D. Parks,et al.  The epidemiology of invasive pneumococcal disease in Alaska, 1986-1990--ethnic differences and opportunities for prevention. , 1994, The Journal of infectious diseases.

[28]  W. Heyward,et al.  Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaska Native infants. The Alaska H. influenzae Vaccine Study Group. , 1990, The New England journal of medicine.

[29]  J. Eskola,et al.  Efficacy of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in infancy. , 1987, The New England journal of medicine.

[30]  B. Gray,et al.  Epidemiologic studies of Streptococcus pneumoniae in infants: acquisition, carriage, and infection during the first 24 months of life. , 1980, The Journal of infectious diseases.